Aminopyrimidines useful as kinase inhibitors

Disclosed is N-(5-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(3-cyclopropyl-3-fluoroazetidin-2-yl)pyrimidin-2-ylthio)pyridin-2-yl)-3,3,3- trifluoropropanamide represented by structural formula (I-21) or a pharmaceutically acceptable salt thereof, which inhibit Aurora protein kinase activity and are suitab...

Full description

Saved in:
Bibliographic Details
Main Authors Robinson Daniel, Fraysse Damien, Davis Chris, Boyall Dean, Binch Hayley, Studley John, Pinder Joanne, Rutherford Alistair, Mortimore Michael, Everitt Simon, Ramaya Sharn, O'donnell Michael, Miller Andrew
Format Patent
LanguageEnglish
Published 27.06.2014
Subjects
AGRICULTURE
ANIMAL HUSBANDRY
BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES
FISHING
FORESTRY
HUMAN NECESSITIES
HUNTING
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PEST REPELLANTS OR ATTRACTANTS
PLANT GROWTH REGULATORS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF
TRAPPING
Online AccessGet full text

Cover

More Information
Summary:Disclosed is N-(5-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(3-cyclopropyl-3-fluoroazetidin-2-yl)pyrimidin-2-ylthio)pyridin-2-yl)-3,3,3- trifluoropropanamide represented by structural formula (I-21) or a pharmaceutically acceptable salt thereof, which inhibit Aurora protein kinase activity and are suitable for treating a proliferative disorder is selected from melanoma, myeloma, leukemia, lymphoma, neuroblastoma, or a cancer selected from colon, breast, gastric, ovarian, cervical, lung, central nervous system, renal, prostate, bladder, pancreatic, brain, head and neck, kidney, liver, melanoma, sarcoma, or thyroid cancer.
Bibliography:Application Number: NZ20060606259